EGFR and non-small cell lung carcinoma: Activated EGFR signaling plays critical roles in driving NSCLC tumorigenesis and progression by activating two major downstream pathways in a kinase-dependent manner, i.e., the Ras/ERK1/2 and the PI3K/AKT4,5.